BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30061240)

  • 1. Tumor Budding
    Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
    Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
    Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
    Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
    Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
    PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
    Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
    Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 9. LC‑MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells.
    Peng W; Tan S; Xu Y; Wang L; Qiu D; Cheng C; Lin Y; Liu C; Li Z; Li Y; Zhao Y; Li Q
    Oncol Rep; 2018 Aug; 40(2):1026-1034. PubMed ID: 29989648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
    Sun CY; Chiang JM; Chen TC; Hung HY; You JF
    World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
    Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
    Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
    Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
    Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
    Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
    Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
    Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
    Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
    Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
    [No Abstract]   [Full Text] [Related]  

  • 20. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.